Isoprenaline hydrochloride Macure 0.2 mg/ml concentrate for solution for infusion
Authorisation PA23199/001/001 · Macure Pharma ApS
- Licence holder
- Macure Pharma ApS (all products →)
- Active substance
- Isoprenaline hydrochloride
- Dosage form
- Concentrate for solution for infusion
- Route of administration
- Intravenous use
- ATC code
- C01CA02
- First authorised
- 23/07/2021
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Generic application (Article 10(1) of Directive No 2001/83/EC)
Isoprenaline hydrochloride: supply and approvals
2 authorised products on the HPRA list contain Isoprenaline hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 21 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 21 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 21 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 5 years (since 23 July 2021). The HPRA list marks it as marketed in Ireland.
Other medicines with Isoprenaline hydrochloride in Ireland
1 other product on the HPRA list contains Isoprenaline hydrochloride, from 1 licence holder; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Labrycor 0.2 mg/ml concentrate for solution for infusion | Macure Healthcare Limited | National authorisation (PA) | Not marketed |
The licence holder
Macure Pharma ApS holds 3 products on the HPRA list, with 3 different active substances; 2 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.